Axsome Therapeutics Inc. (19X)
FSX
149.65
-2.60 (-1.71%)
Closed
Oct 9, 2026
Day's Range
149.35152.35
52 wk Range
100.85221.20
Financial Statements - 19X - Axsome Therapeutics Inc.
Revenue
638.49M▲ 95.5%
Net Income
-183.17M▲ 24.7%Net Margin -28.7%
EBITDA
-160.17M▲ 22.6%
Free Cash Flow
-93.88M▲ 13.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 638.49M | 326.52M | 270.60M | 50.03M | 0 | 0 |
| Cost of Goods | 47.47M | 28.19M | 26.06M | 5.19M | 0 | 0 |
| Gross Profit | 591.01M | 298.33M | 244.53M | 44.83M | 0 | 0 |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -169.23M | -213.71M | -182.90M | -176.50M | -124.70M | -99.08M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -7.91M | -23.80M | -48.91M | -3.29M | - | -1.24M |
| Pre Tax Income | -183.70M | -243.08M | -238.27M | -187.13M | -130.40M | -102.90M |
| Income Tax | -530K | 71.96K | 960K | 0 | 0 | - |
| Net Income | -183.17M | -243.15M | -239.23M | -187.13M | -130.40M | -102.90M |
| EPS Basic | -3.68 | -5.99 | -5.27 | -4.6 | -3.47 | -2.77 |
| EPS Diluted | -3.68 | -5.99 | -5.27 | -4.6 | -3.47 | -2.77 |
| Basic Shares Outstanding | 49.74M | 40.56M | 47.31M | 41.74M | 38.62M | 38.20M |
| Diluted Shares Outstanding | 49.74M | 40.56M | 47.31M | 41.74M | 38.62M | 38.20M |
| Ebit | -177.14M | -237.52M | -231.82M | -179.79M | -124.70M | -100.33M |
| Ebitda | -160.17M | -206.97M | -176.07M | -172.09M | -124.63M | -99.01M |
| Net Income Continuous Operations | -183.17M | -243.15M | -239.23M | -187.13M | -130.40M | -102.90M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
